Chai Discovery deployed Chai-3, a next generation antibody design model that the company describes as roughly doubling the success rate of Chai-2 and binding more tightly to harder targets. Date recorded here is the date of the trade coverage confirming deployment; the company has not published a precise release date for Chai-3, and this record does not assert one.
Our readFor an R&D buyer the question is whether a model generation actually changes the design cycle or only the benchmark. The reported doubling is a vendor claim measured against the company's own prior model, not an independent comparison against competing methods, and no candidate designed by these models has published clinical results. What is verifiable is that named pharmaceutical organizations have licensed the platform into production R&D, including at least one custom model trained on a customer's proprietary data. That structure is the thing to scrutinize in procurement: a custom model trained on internal discovery data creates a different dependency, and different exit economics, than licensing a general model.